Lupus Nephritis - Epidemiology Forecast - 2034
Description
Key Highlight
Lupus nephritis is one of the most serious complications of SLE, with the potential to progress to end-stage renal disease (ESRD). It affects approximately 40–60% of SLE patients, and among those, 10–30% may advance to ESRD despite therapy.
In the US, the rising burden of lupus nephritis is partly driven by increasing racial diversity, as populations with higher susceptibility to severe SLE, such as Black, Hispanic, and Asian individuals, continue to grow. Alongside improved survival in SLE and greater diagnostic vigilance, these factors are contributing to the steady rise in lupus nephritis diagnoses.
The total diagnosed prevalent cases of lupus nephritis in the 7MM were approximately 385,000 in 2024, and this number is projected to increase by 2034.
Lupus nephritis is predominantly seen in adults, especially women aged 20–40, but pediatric cases, though fewer, often present with more severe renal involvement. This age-related variation is influenced by immune maturity, hormonal factors, and genetic predisposition.
Among the histological subtypes, Class IV remains the most prevalent and carries the worst prognosis, often associated with non-remission and high relapse rates. In contrast, Classes I and II are associated with milder disease and better outcomes, whereas Class V, though less common, poses its challenges due to frequent proteinuria and overlap with proliferative forms, reinforcing the need for timely diagnosis and personalized treatment strategies.
Lupus nephritis incidence rate peaked around 2020 and has since declined, while prevalence continues to rise due to improved survival. This suggests a growing but gradually stabilizing patient burden over time.
Spain recorded the highest SLE prevalence rate among the EU4 and the UK, suggesting a relatively greater concentration of diagnosed cases within its population.
DelveInsight’s ‘Lupus nephritis – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain), and the United Kingdom
Japan
Study Period: 2020–2034
Lupus Nephritis Disease Understanding and Treatment Algorithm
Lupus Nephritis Overview
Lupus nephritis is a severe, organ-threatening manifestation of SLE, developed in 40–60% of patients with SLE. Signs of lupus nephritis include hematuria (blood in the urine) and proteinuria (protein in the urine). Lupus nephritis is more common in women and occurs in patients aged 20–40. Lupus nephritis is categorized into six classes (I–VI), with Classes III (focal proliferative, ~30%), IV (diffuse proliferative, ~40%), and V (membranous, ~20%) being the most prevalent and consistently observed across patient populations.
Lupus Nephritis Diagnosis
Lupus nephritis is diagnosed using a combination of urine tests, blood tests, and a kidney biopsy. Early indicators may include blood in the urine, foamy urine, elevated blood pressure, and swelling in the feet. Essential diagnostic evaluations include:
Urine test
Blood test
Kidney ultrasound
Kidney biopsy
Further details related to diagnosis and treatment are provided in the report…
Lupus Nephritis Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases, Age-specific Diagnosed Prevalent Cases, Diagnosed Prevalent Cases by Class, Total Treated Cases of Lupus Nephritis in the 7MM market covering the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The epidemiology segment also provides the Lupus nephritis epidemiology data and findings across the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The total Diagnosed Prevalent Cases of Lupus Nephritis in the US comprised nearly 218,000 cases in 2024 and are projected to increase during the forecast period.
The total diagnosed prevalent cases of Lupus nephritis in the EU4 and the UK were nearly 130,000 in 2024.
The US contributed the largest prevalent population of Lupus nephritis, accounting for roughly ~60% of the 7MM in 2024.
In EU4 and the UK, the diagnosed prevalent cases of lupus nephritis were found to be maximum in Spain, followed by the UK. While the least number of cases were found in France in 2024.
In 2024, the diagnosed prevalent cases of lupus nephritis in the US were distributed as approximately 9% in individuals aged <18 years and around 91% in those aged =18 years.
In Japan, Class IV was the most prevalent form of lupus nephritis in 2024, with around 18,000 diagnosed cases, reflecting a consistently high disease burden. Class III followed as the second most common subtype, with around 6,800 reported cases.
Scope of the Report
The report covers a segment of an executive summary and a descriptive overview of Lupus nephritis, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the Lupus nephritis epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Lupus Nephritis Report Insights
Patient population
Country-wise epidemiology distribution
Lupus Nephritis Report Key Strengths
10-year forecast
7MM coverage
Lupus nephritis epidemiology segmentation
Lupus Nephritis Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
FAQs
What are the patient burden trends of Lupus nephritis in the seven major markets? Historically, why is the prevalence rate of Lupus nephritis increasing while its incidence rate is declining across the 7MM?
Lupus nephritis is associated with significant morbidity and mortality, particularly among younger women and immunocompromised populations. Each disease flare not only accelerates cumulative kidney damage but also increases the risk of progression to ESRD. What are the renal survival and mortality rates (%) across the 7MM following each lupus nephritis flare or recurrence?
What are the disease risk, burden, and unmet needs of Lupus nephritis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Lupus nephritis?
What is the historical Lupus nephritis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of Lupus nephritis at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalence of Lupus nephritis during the study period (2020–2034)?
At what CAGR is the population expected to grow across the 7MM during the study period (2020–2034)?
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the Lupus nephritis market.
To understand the future market competition in the Lupus nephritis market, an insightful review of the key market drivers and barriers.
Quantify patient populations in the global Lupus nephritis market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Lupus nephritis in the US, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
The Lupus nephritis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and highlights disease trends over a 10-year forecast period using reputable sources.
Lupus nephritis is one of the most serious complications of SLE, with the potential to progress to end-stage renal disease (ESRD). It affects approximately 40–60% of SLE patients, and among those, 10–30% may advance to ESRD despite therapy.
In the US, the rising burden of lupus nephritis is partly driven by increasing racial diversity, as populations with higher susceptibility to severe SLE, such as Black, Hispanic, and Asian individuals, continue to grow. Alongside improved survival in SLE and greater diagnostic vigilance, these factors are contributing to the steady rise in lupus nephritis diagnoses.
The total diagnosed prevalent cases of lupus nephritis in the 7MM were approximately 385,000 in 2024, and this number is projected to increase by 2034.
Lupus nephritis is predominantly seen in adults, especially women aged 20–40, but pediatric cases, though fewer, often present with more severe renal involvement. This age-related variation is influenced by immune maturity, hormonal factors, and genetic predisposition.
Among the histological subtypes, Class IV remains the most prevalent and carries the worst prognosis, often associated with non-remission and high relapse rates. In contrast, Classes I and II are associated with milder disease and better outcomes, whereas Class V, though less common, poses its challenges due to frequent proteinuria and overlap with proliferative forms, reinforcing the need for timely diagnosis and personalized treatment strategies.
Lupus nephritis incidence rate peaked around 2020 and has since declined, while prevalence continues to rise due to improved survival. This suggests a growing but gradually stabilizing patient burden over time.
Spain recorded the highest SLE prevalence rate among the EU4 and the UK, suggesting a relatively greater concentration of diagnosed cases within its population.
DelveInsight’s ‘Lupus nephritis – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain), and the United Kingdom
Japan
Study Period: 2020–2034
Lupus Nephritis Disease Understanding and Treatment Algorithm
Lupus Nephritis Overview
Lupus nephritis is a severe, organ-threatening manifestation of SLE, developed in 40–60% of patients with SLE. Signs of lupus nephritis include hematuria (blood in the urine) and proteinuria (protein in the urine). Lupus nephritis is more common in women and occurs in patients aged 20–40. Lupus nephritis is categorized into six classes (I–VI), with Classes III (focal proliferative, ~30%), IV (diffuse proliferative, ~40%), and V (membranous, ~20%) being the most prevalent and consistently observed across patient populations.
Lupus Nephritis Diagnosis
Lupus nephritis is diagnosed using a combination of urine tests, blood tests, and a kidney biopsy. Early indicators may include blood in the urine, foamy urine, elevated blood pressure, and swelling in the feet. Essential diagnostic evaluations include:
Urine test
Blood test
Kidney ultrasound
Kidney biopsy
Further details related to diagnosis and treatment are provided in the report…
Lupus Nephritis Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases, Age-specific Diagnosed Prevalent Cases, Diagnosed Prevalent Cases by Class, Total Treated Cases of Lupus Nephritis in the 7MM market covering the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The epidemiology segment also provides the Lupus nephritis epidemiology data and findings across the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The total Diagnosed Prevalent Cases of Lupus Nephritis in the US comprised nearly 218,000 cases in 2024 and are projected to increase during the forecast period.
The total diagnosed prevalent cases of Lupus nephritis in the EU4 and the UK were nearly 130,000 in 2024.
The US contributed the largest prevalent population of Lupus nephritis, accounting for roughly ~60% of the 7MM in 2024.
In EU4 and the UK, the diagnosed prevalent cases of lupus nephritis were found to be maximum in Spain, followed by the UK. While the least number of cases were found in France in 2024.
In 2024, the diagnosed prevalent cases of lupus nephritis in the US were distributed as approximately 9% in individuals aged <18 years and around 91% in those aged =18 years.
In Japan, Class IV was the most prevalent form of lupus nephritis in 2024, with around 18,000 diagnosed cases, reflecting a consistently high disease burden. Class III followed as the second most common subtype, with around 6,800 reported cases.
Scope of the Report
The report covers a segment of an executive summary and a descriptive overview of Lupus nephritis, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
A detailed review of the Lupus nephritis epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.
Lupus Nephritis Report Insights
Patient population
Country-wise epidemiology distribution
Lupus Nephritis Report Key Strengths
10-year forecast
7MM coverage
Lupus nephritis epidemiology segmentation
Lupus Nephritis Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
FAQs
What are the patient burden trends of Lupus nephritis in the seven major markets? Historically, why is the prevalence rate of Lupus nephritis increasing while its incidence rate is declining across the 7MM?
Lupus nephritis is associated with significant morbidity and mortality, particularly among younger women and immunocompromised populations. Each disease flare not only accelerates cumulative kidney damage but also increases the risk of progression to ESRD. What are the renal survival and mortality rates (%) across the 7MM following each lupus nephritis flare or recurrence?
What are the disease risk, burden, and unmet needs of Lupus nephritis? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Lupus nephritis?
What is the historical Lupus nephritis patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What would be the forecasted patient pool of Lupus nephritis at the 7MM level?
Out of the countries mentioned above, which country would have the highest prevalence of Lupus nephritis during the study period (2020–2034)?
At what CAGR is the population expected to grow across the 7MM during the study period (2020–2034)?
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the Lupus nephritis market.
To understand the future market competition in the Lupus nephritis market, an insightful review of the key market drivers and barriers.
Quantify patient populations in the global Lupus nephritis market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Lupus nephritis in the US, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
The Lupus nephritis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and highlights disease trends over a 10-year forecast period using reputable sources.
Table of Contents
87 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. Key Events
- 4.1. Upcoming Key Catalysts
- 4.2. Key Transactions and Collaborations
- 4.3. News Flow
- 5. Epidemiology and Market Forecast Methodology
- 6. Lupus Nephritis Market Overview at a Glance
- 6.1. Clinical Landscape Analysis (By Phase, RoA, and Molecule Type)
- 6.2. Market Share (%) Distribution of Lupus Nephritis by Therapy in 2024
- 6.3. Market Share (%) Distribution of Lupus Nephritis by Therapy in 2034
- 7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Types of Lupus
- 7.3. Causes and Risk Factors
- 7.3.1. Genetic Factors
- 7.3.2. Immunologic Factors
- 7.3.3. Risk Factors
- 7.4. Signs and Symptoms of Lupus Nephritis
- 7.5. Classification of Lupus Nephritis
- 7.6. Pathophysiology of Lupus Nephritis
- 7.7. Biomarkers of Lupus Nephritis
- 7.8. Complications of Lupus Nephritis
- 7.9. Diagnosis
- 7.9.1. Blood Tests
- 7.9.2. Twenty-four-hour Urine Collection
- 7.9.3. Urine Tests
- 7.9.4. Kidney Biopsy
- 7.1. Diagnosis Algorithm
- 7.11. Differential Diagnosis
- 8. Treatment of Lupus Nephritis
- 8.1. Classes III and IV Induction Therapy
- 8.2. Class V Induction Therapy
- 8.3. Treatment Options for Kidney Failure
- 8.4. Treatment Algorithm
- 8.5. Guidelines of Lupus Nephritis
- 8.5.1. American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis (2024)
- 8.5.2. European Evidence-based Recommendations for the Diagnosis and Treatment of Childhood-onset Lupus Nephritis: The SHARE Initiative (2017)
- 8.5.3. Kidney Disease Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Diagnosis and Management of Lupus Nephritis
- 9. Epidemiology and Patient Population
- 9.1. Key Findings
- 9.2. Assumptions and Rationale
- 9.3. Total Diagnosed Prevalent Cases of SLE in the 7MM
- 9.4. Total Diagnosed Prevalent Cases of Lupus Nephritis in the 7MM
- 9.5. Total Treated Cases of Lupus Nephritis in the 7MM
- 9.6. The United States
- 9.6.1. Total Diagnosed Prevalent Cases of Lupus Nephritis in the US
- 9.6.2. Age-specific Diagnosed Prevalent Cases of Lupus Nephritis in the US
- 9.6.3. Diagnosed Prevalent Cases of Lupus Nephritis by Class in the US
- 9.6.4. Total Treated Cases of Lupus Nephritis in the US
- 9.7. EU4 and the UK
- 9.7.1. Total Diagnosed Prevalent Cases of Lupus Nephritis in EU4 and the UK
- 9.7.2. Age-specific Diagnosed Prevalent Cases of Lupus Nephritis in EU4 and the UK
- 9.7.3. Diagnosed Prevalent Cases of Lupus Nephritis by Class in EU4 and the UK
- 9.7.4. Total Treated Cases of Lupus Nephritis in EU4 and the UK
- 9.8. Japan
- 9.8.1. Total Diagnosed Prevalent Cases of Lupus Nephritis in Japan
- 9.8.2. Age-specific Diagnosed Prevalent Cases of Lupus Nephritis in Japan
- 9.8.3. Diagnosed Prevalent Cases of Lupus Nephritis by Class in Japan
- 9.8.4. Total Treated Cases of Lupus Nephritis in Japan
- 10. KOL Views
- 11. Appendix
- 11.1. Bibliography
- 11.2. Report Methodology
- 12. DelveInsight Capabilities
- 13. Disclaimer
- 14. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
